Elicio Therapeutics, Inc (ELTX)

Over the past six months, Elicio Therapeutics' stock has been influenced by positive clinical trial updates, including Phase 2 AMPLIFY-7P data for ELI-002 7P. The company secured $10 million in non-dilutive financing in June 2025 and raised approximately $11.1 million through its at-the-market program by November 2025. Marc J. Wolfgang was appointed as Chief Technology Officer in November 2025. The stock price gained 9.33% on February 6, 2026, but has underperformed the S&P500 Index by -7.56% over the past six months. Analysts have provided an average twelve-month stock price forecast of $13.00, and insider sentiment is positive due to open-market purchases.

As a clinical-stage biotechnology company, Elicio Therapeutics, Inc. does not have commercially available products or services, so traditional demand seasonality is not applicable. The demand for Elicio Therapeutics is primarily driven by investor interest, clinical trial progress, regulatory milestones, and sentiment towards the immuno-oncology sector, which are not subject to seasonal fluctuations.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, operating in the immuno-oncology industry. Their platform targets lymph nodes and their major product candidates include ELI-002, a vaccine in Phase II trials targeting KRAS mutations, and ELI-007 and ELI-008, vaccines in preclinical studies for B-RAF and p53 driven cancers, respectively.

Elicio Therapeutics, Inc. is headquartered in Boston/Cambridge, Massachusetts, United States. Its operations are focused on research and development, with clinical trials conducted in various locations. The company does not have a broad international geographic footprint for commercial product sales at this stage.

Elicio Therapeutics' brand reputation has been positively influenced by strong clinical trial results from its Phase 2 AMPLIFY-7P trial, the strategic appointment of Marc J. Wolfgang as Chief Technology Officer, and successful financing efforts. There is no readily available information indicating any significant negative events that have affected Elicio Therapeutics' reputation in the past year.

Elicio Therapeutics, Inc. has a diverse ownership structure, with retail investors holding approximately 52% of shares and insiders owning 33%. Yekaterina Chudnovsky is the largest individual shareholder, holding 31% of outstanding shares. Major institutional owners include Knoll Capital Management, LLC, and Vanguard Group Inc. As of December 31, 2025, institutional investors and hedge funds held a total of 1,978,657 shares across 47 institutional owners, representing approximately 35.03% of the stock.